Cobomarsen (MRG-106) is an oligonucleotide inhibitor ofmiR-155. Cobomarsen inhibits multiple gene pathways associated with cell survival (includingJAK/STAT,MAPK/ERKandPI3K/AKT). Cobomarsen can be used for the research of B-cell lymphoma^[1][2].

Cobomarsen (10 μM; 48-96 h) reduces cell proliferation and induces apoptosis in U2932, OCI-LY3, and RCK8 cells^[2].
Cobomarsen (10 μM; 72 h) significantly increases the expression of the four direct targets in the cell lines that overexpress miR-155^[1].
Cobomarsen (10 μM; 12 days) reduces cellular proliferation and induces apoptosis in MF and HTLV-1+ CTCL cells^[1].
Cobomarsen (10-50 μM; 7 days) reduces phosphorylation of the downstream signalling proteins AKT, ERK1/2, and STAT-3 in primary human activated T cells or MF cell lines^[1].

Cobomarsen (1 mg/kg; i.v. on days 0, 2, 4, and 7) inhibits tumor growth in mice carrying U2932 cells xenografts^[2].

4736.00

1848257-52-2

RNA, (P-thio)((2'-O,4'-C-methylene)m5C-dA-(2'-O,4'-C-methylene)m5C-dG-dA- (2'-O,4'-C-methylene)m5U-(2'-O,4'-C-methylene)m5U-dA-(2'-O,4'-Cmethylene)G-dC-(2'-O,4'-C-methylene)A-(2'-O,4'-C-methylene)m5U-(2'-O,4'-Cmethylene)m5U-(2'-O,4'-C-methylene)A)

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.